Improving colorectal cancer treatment: integrating synbiotics therapy with various treatment approaches

Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide. Despite advancements in conventional therapies, there is a critical need for innovative strategies to enhance treatment efficacy and patient outcomes. Various growth factors and novel nutrients, including probiotics and prebiotics, have been tested in experimental models to combat mucositis. Prebiotics are non-digestible compounds that selectively stimulate the growth and activity of beneficial microbes in the gut microbiota and provide health benefits to the host. Synbiotics are symbiotic combinations of probiotics and prebiotics that can have better effects than either of these agents alone. This paper explores the potential of integrating synbiotics therapy—comprising prebiotics and probiotics—into existing CRC treatment regimens. Synbiotics may improve gut microbiota balance, enhance immune response, and mitigate treatment-related side effects, thus offering a complementary approach to conventional therapies such as chemotherapy, radiation, and targeted therapies. We review current evidence on the role of synbiotics in CRC management, highlighting their mechanisms of action, potential benefits, and clinical applications. Additionally, we discuss challenges and future directions for research in this field. By synergizing synbiotics therapy with diverse treatment modalities, we aim to pave the way for more effective, personalized approaches to colorectal cancer care.

کلیدواژه ها:

colorectal cancer ، Synbiotics ، Treatment integration ، probiotics ، Prebiotics ، treatment efficacy